Who are ARM B: IV iron + epoietin zeta sequence's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ARM A : IV iron + epoietin zeta, Iron Sucrose + Erythropoietin, Oral Iron + Erythropoietin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arm-b-iv-iron-epoietin-zeta-sequence.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ARM B: IV iron + epoietin zeta sequence — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ARM B: IV iron + epoietin zeta sequence (ARM B: IV iron + epoietin zeta sequence) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron supplement + Erythropoiesis-stimulating agent (ESA). Area: Hematology/Oncology.

marketed Iron supplement + Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ARM B: IV iron + epoietin zeta sequence (ARM B: IV iron + epoietin zeta sequence) — Centre Francois Baclesse. This combination therapy replenishes iron stores and stimulates red blood cell production to treat anemia.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ARM B: IV iron + epoietin zeta sequence TARGET	ARM B: IV iron + epoietin zeta sequence	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
ARM A : IV iron + epoietin zeta	ARM A : IV iron + epoietin zeta	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
Iron Sucrose + Erythropoietin	Iron Sucrose + Erythropoietin	American Regent, Inc.	phase 3	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Iron (ferric hydroxide complex) + Erythropoietin receptor (EPOR)
Oral Iron + Erythropoietin	Oral Iron + Erythropoietin	American Regent, Inc.	phase 3	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Iron (Fe2+/Fe3+) and erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron supplement + Erythropoiesis-stimulating agent (ESA) class)

American Regent, Inc. · 2 drugs in this class
Centre Francois Baclesse · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARM B: IV iron + epoietin zeta sequence — Competitive Intelligence Brief. https://druglandscape.com/ci/arm-b-iv-iron-epoietin-zeta-sequence. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab